BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37185904)

  • 21. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-582-5p Is a Tumor Suppressor microRNA Targeting the Hippo-YAP/TAZ Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhu B; V M; Finch-Edmondson M; Lee Y; Wan Y; Sudol M; DasGupta R
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EP4 receptor promotes invadopodia and invasion in human breast cancer.
    Tönisen F; Perrin L; Bayarmagnai B; van den Dries K; Cambi A; Gligorijevic B
    Eur J Cell Biol; 2017 Mar; 96(2):218-226. PubMed ID: 28094049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.
    Wang D; Li Z; Li X; Yan C; Yang H; Zhuang T; Wang X; Zang Y; Liu Z; Wang T; Jiang R; Su P; Zhu J; Ding Y
    J Exp Clin Cancer Res; 2022 Jul; 41(1):219. PubMed ID: 35820928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Invadopodium Formation and Gelatin Degradation in Vitro.
    Clarke MJ; Battagin S; Coppolino MG
    Methods Mol Biol; 2024; 2747():141-149. PubMed ID: 38038938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invadosomes are coming: new insights into function and disease relevance.
    Paterson EK; Courtneidge SA
    FEBS J; 2018 Jan; 285(1):8-27. PubMed ID: 28548369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorting nexin 9 negatively regulates invadopodia formation and function in cancer cells.
    Bendris N; Stearns CJ; Reis CR; Rodriguez-Canales J; Liu H; Witkiewicz AW; Schmid SL
    J Cell Sci; 2016 Jul; 129(14):2804-16. PubMed ID: 27278018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invadopodia-mediated ECM degradation is enhanced in the G1 phase of the cell cycle.
    Bayarmagnai B; Perrin L; Esmaeili Pourfarhangi K; Graña X; Tüzel E; Gligorijevic B
    J Cell Sci; 2019 Oct; 132(20):. PubMed ID: 31533971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of Tks adaptor proteins in invadopodia formation, growth and metastasis of melanoma.
    Iizuka S; Abdullah C; Buschman MD; Diaz B; Courtneidge SA
    Oncotarget; 2016 Nov; 7(48):78473-78486. PubMed ID: 27802184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation.
    Landry NM; Rattan SG; Filomeno KL; Meier TW; Meier SC; Foran SJ; Meier CF; Koleini N; Fandrich RR; Kardami E; Duhamel TA; Dixon IMC
    Basic Res Cardiol; 2021 Apr; 116(1):25. PubMed ID: 33847835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells.
    Yamaguchi H; Takeo Y; Yoshida S; Kouchi Z; Nakamura Y; Fukami K
    Cancer Res; 2009 Nov; 69(22):8594-602. PubMed ID: 19887621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
    Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
    J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis.
    Boopathy GTK; Hong W
    Front Cell Dev Biol; 2019; 7():49. PubMed ID: 31024911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion.
    Desai B; Ma T; Chellaiah MA
    J Biol Chem; 2008 May; 283(20):13856-66. PubMed ID: 18337256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
    Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
    J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function.
    Sun C; De Mello V; Mohamed A; Ortuste Quiroga HP; Garcia-Munoz A; Al Bloshi A; Tremblay AM; von Kriegsheim A; Collie-Duguid E; Vargesson N; Matallanas D; Wackerhage H; Zammit PS
    Stem Cells; 2017 Aug; 35(8):1958-1972. PubMed ID: 28589555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.
    Komatsu N; Kajiya M; Motoike S; Takewaki M; Horikoshi S; Iwata T; Ouhara K; Takeda K; Matsuda S; Fujita T; Kurihara H
    Stem Cell Res Ther; 2018 Dec; 9(1):342. PubMed ID: 30526677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki/Yap/Taz in the nucleus.
    Cho YS; Li S; Wang X; Zhu J; Zhuo S; Han Y; Yue T; Yang Y; Jiang J
    Genes Dev; 2020 Jan; 34(1-2):53-71. PubMed ID: 31857346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
    Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
    Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.